Emergent BioSolutions: Executive Chairman retiring Apr 1; bonuses at 75% of target; Saran, Fox promoted

Emergent BioSolutions Inc.

Fuad El-Hibri to retire as Executive Chairman effective April 1, 2022; no 2022 equity grant.
2021 cash bonuses paid at ~75% of target due to below-target performance; CEO Kramer received $900,000.
Atul Saran promoted to EVP, Chief Strategy and Development Officer effective March 1, 2022.
Jennifer Fox promoted to EVP, External Affairs, General Counsel and Corporate Secretary effective March 1, 2022.
One-time retention equity awards granted to NEOs (excluding El-Hibri); Kramer got $900K in PSUs.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Fuad El-Hibri

Executive Chairman

EBS · Emergent BioSolutions Inc.

Effective: 2022-04-01
Filed: February 22, 2022, 6:59 PM ET

The Executive Chairman, who has announced that he will retire from the Company effective April 1, 2022, will not receive an annual equity grant.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Fuad El-Hibri departed as Executive Chairman at Emergent BioSolutions Inc..

Action: retire
Role: Executive Chairman

Exact text from the filing

The Executive Chairman, who has announced that he will retire from the Company effective April 1, 2022, will not receive an annual equity grant.

View on SEC.gov

Emergent BioSolutions Inc. filing history →

Source: SEC EDGAR

accession 0001367644-22-000009

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.